AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04878965 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smartwatch
Description: Smartwatch apparatus to measure strong emotions (e.g., anxiety)
Study NCT05344586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching program with neural load
Description: Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
Study NCT05344586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching program without neural load
Description: Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
Study NCT06437158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Study NCT05728372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-pembrolizumab
Description: Given IV
Study NCT05728372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05728372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT06022003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaCITIDine Oral Tablet
Description: AML study treatment
Study NCT06022003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xospata
Description: R/R FLT3-mutated AML standard treatment
Study NCT04936815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
Study NCT05148806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: self-administered lateral flow assays
Description: The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
Study NCT06722950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Study NCT05052424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of cytokines and immun cell related markers
Description: blood samples
Study NCT06189456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLUgel A
Description: BLUgel A: Hyaluronic Acid Eye Drops 0.30%
Study NCT06189456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLUyal A
Description: BLUyal A:Hyaluronic Acid Eye Drops 0.15%
Study NCT04916327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
Study NCT04916327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study NCT05725447 — intervention group
Intervention type: OTHER
Intervention: Validity and reliability study
Description: Face-to-face questionnaire study
Study NCT05377138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online PEP/PrEP delivery
Description: Delivery of PEP or PrEP after online consultation and HIVST image upload.
Study NCT06438055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
Study NCT04440813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Training by Clinicians
Description: Training in the use of PPE and education about the risks of blood exposure.
Study NCT04440813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Education from Traditional Healers and Clinicians
Description: Training in the use of PPE and education about the risks of blood exposure.
Study NCT04556279 — intervention group
Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
Study NCT04556279 — intervention group
Intervention type: DRUG
Intervention: Aldosterone Antagonist
Description: Medical treatment of primary hyperaldosteronism.
Study NCT05275595 — intervention group
Intervention type: OTHER
Intervention: Medical records review
Description: Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January.
Study NCT05275595 — intervention group
Intervention type: OTHER
Intervention: Medical records review
Description: Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
Study NCT06267391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCET Treatment
Description: Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
Study NCT06722950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Study NCT06267391 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
Study NCT05580939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: They use Web-based Simulation Application for 4 weeks
Study NCT05579808 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural Analgesia
Description: Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
Study NCT05811169 — intervention group
Intervention type: GENETIC
Intervention: Next generation sequencing
Description: Next generation sequencing
Study NCT05495867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: implant placement in edentulous area
Study NCT05495867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: implant placement in edentulous area
Study NCT06722950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：3 times a day (daily), taken with boiled water.
Study NCT06722950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC591
Description: AC591 : 3 times a day (daily), taken with boiled water.
Study NCT04693585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - live
Description: mHealth education and social support intervention, synchronous via call
Study NCT04693585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSSSAGE - asynchronous
Description: mHealth education and social support intervention, asynchronous via text
Study NCT05387629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Nursing students will be trained through social media.
Study NCT06464445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic iTBS
Description: iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds
Study NCT06464445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic iTBS
Description: iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds
Study NCT06464445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic-Long iTBS
Description: iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds
Study NCT05695885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: behavioral counseling
Study NCT05695885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as usual (SAU)
Description: behavioral counseling normally provided
Study NCT05405335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Positioning Maneuver
Description: intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
Study NCT06722963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
Study NCT06722963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
Study NCT06722209 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: polyethylene glycol (Protocol I)
Description: Intestinal preparation protocol with polyethylene glycol (Protocol I)
Study NCT06723067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable wireless breast pump
Description: As above
Study NCT06722391 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level
Study NCT06722391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level
Study NCT06722391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Group will receive exercise training.
Study NCT06722391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Group will receive exercise training.
Study NCT06722820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPH-5
Description: LPH-5
Study NCT06722820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06393972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG BID
Description: Tofacitinib 5 MG BID
Study NCT06724783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Description: Implant placement with simultaneous GBR covered with a collagen membrane
Study NCT05582772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GA+M Intervention
Description: Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
Study NCT05582772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RSM intervention
Description: Telephone-based, symptom management of patients with cancer
Study NCT05582772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GA+RSM intervention
Description: Combining a geriatric assessment and remote symptom control
Study NCT05022966 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Individuals did not received any intervention.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 200 mg
Description: 200 mg oral tablet daily
Study NCT05451771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FISH assay
Description: Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet, 400 mg
Description: 400 mg oral tablet daily
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral, 10 mg
Description: 10 mg oral tablet weekly
Study NCT06724783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Description: Implant placement with simultaneous GBR covered with a collagen membrane
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral, 20 mg
Description: 20 mg oral tablet weekly
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral, 20 mg
Description: 20 mg oral tablet weekly
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab Injection
Description: Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
Study NCT05451771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax MTD with Dexamethasone
Description: Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
Study NCT05748340 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Unilateral cleft lip repair
Description: Surgical repair unilateral cleft lip
Study NCT05457569 — intervention group
Intervention type: OTHER
Intervention: Focus group (FC) - WP1
Description: 3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk
Study NCT05457569 — intervention group
Intervention type: OTHER
Intervention: Child Neurodevelopment Questionnaires - WP2
Description: during the 4th month of corrected infant age
Study NCT05457569 — intervention group
Intervention type: OTHER
Intervention: Evaluation of compliance for the acquired skills in terms of development support - WP2
Description: during the 4th month of corrected infant age
Study NCT05457569 — intervention group
Intervention type: OTHER
Intervention: Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2
Description: at the end of the study
Study NCT05457569 — intervention group
Intervention type: OTHER
Intervention: 4 Focus Group (FC) - WP2
Description: * Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice
Study NCT04847934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distraction methods
Description: distraction methods
Study NCT05981027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan bent leg raise technique
Description: In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
Study NCT05981027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching exercise
Description: The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
Study NCT05500313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypno-breastfeeding Education
Description: The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
Study NCT05500313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Standart Breastfeeding Education
Description: The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
Study NCT05941156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD56 CAR T
Description: CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.